Loading…
β-Hydroxybutyrate Protects Against Cisplatin-Induced Renal Damage via Regulating Ferroptosis
Cisplatin is a particularly potent antineoplastic drug. However, its usefulness is restricted due to the induction of nephrotoxicity. More recent research has indicated that β-hydroxybutyrate (β-HB) protects against acute or chronic organ damage as an efficient healing agent. Nonetheless, the therap...
Saved in:
Published in: | Renal failure 2024-12, Vol.46 (1), p.2354918-2354918 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c506t-daad1d418d694003aad4c246c09006ea025af5038be1a2a03a9de49ac343b03d3 |
---|---|
cites | cdi_FETCH-LOGICAL-c506t-daad1d418d694003aad4c246c09006ea025af5038be1a2a03a9de49ac343b03d3 |
container_end_page | 2354918 |
container_issue | 1 |
container_start_page | 2354918 |
container_title | Renal failure |
container_volume | 46 |
creator | Tian, Ruixue Tang, Shuqin Zhao, Jingyu Hao, Yajie Zhao, Limei Han, Xiutao Wang, Xingru Zhang, Lijun Li, Rongshan Zhou, Xiaoshuang |
description | Cisplatin is a particularly potent antineoplastic drug. However, its usefulness is restricted due to the induction of nephrotoxicity. More recent research has indicated that β-hydroxybutyrate (β-HB) protects against acute or chronic organ damage as an efficient healing agent. Nonetheless, the therapeutic mechanisms of β-HB in acute kidney damage caused by chemotherapeutic drugs remain unclear. Our study developed a model of cisplatin-induced acute kidney injury (AKI), which involved the administration of a ketogenic diet or β-HB. We analyzed blood urea nitrogen (BUN) and creatinine (Cr) levels in serum, and used western blotting and immunohistochemical staining to assess ferroptosis and the calcium/calmodulin-dependent kinase kinase 2 (Camkk2)/AMPK pathway. The mitochondrial morphology and function were examined. Additionally, we conducted
and
experiments using selective Camkk2 inhibitor or activator to investigate the protective mechanism of β-HB on cisplatin-induced AKI. Exogenous or endogenous β-HB effectively alleviated cisplatin-induced abnormally elevated levels of BUN and Cr and renal tubular necrosis
. Additionally, β-HB reduced ferroptosis biomarkers and increased the levels of anti-ferroptosis biomarkers in the kidney. β-HB also improved mitochondrial morphology and function. Moreover, β-HB significantly attenuated cisplatin-induced cell ferroptosis and damage
. Furthermore, western blotting and immunohistochemical staining indicated that β-HB may prevent kidney injury by regulating the Camkk2-AMPK pathway. The use of the Camkk2 inhibitor or activator verified the involvement of Camkk2 in the renal protection by β-HB. This study provided evidence of the protective effects of β-HB against cisplatin-induced nephrotoxicity and identified inhibited ferroptosis and Camkk2 as potential molecular mechanisms. |
doi_str_mv | 10.1080/0886022X.2024.2354918 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_43438698fc474643a9cbe4e9d4b17d7a</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_43438698fc474643a9cbe4e9d4b17d7a</doaj_id><sourcerecordid>3056663915</sourcerecordid><originalsourceid>FETCH-LOGICAL-c506t-daad1d418d694003aad4c246c09006ea025af5038be1a2a03a9de49ac343b03d3</originalsourceid><addsrcrecordid>eNpdkt9u0zAUhyMEYt3gEUCRuOEm5fhvnCs0dYxVmgRCIHGDrBPbDanSuNjORF-LB9kz4a7dxLiyfPydTz72ryheEZgTUPAOlJJA6fc5BcrnlAneEPWkmBFBRSWBN0-L2Z6p9tBJcRrjGoAIVdPnxQlTtahrymbFj9s_1dXOBv97105pFzC58nPwyZkUy_MO-zGmctHH7YCpH6vlaCfjbPnFjTiUF7jBzpU3PeZCN90hXXnpQvDb5GMfXxTPVjhE9_K4nhXfLj98XVxV158-Lhfn15URIFNlES2xnCgrGw7A8pYbyqWBBkA6BCpwJYCp1hGkmIHGOt6gYZy1wCw7K5YHr_W41tvQbzDstMde3xV86DSG1JvBaZ57lGzUyvCaS55VpnXcNZa3pLY1Ztf7g2s7tRtnjRtTwOGR9PHJ2P_Unb_RhBDgeYBseHs0BP9rcjHpTR-NGwYcnZ-iZiCklKwhIqNv_kPXfgr5bfdUzTiXNWOZEgfKBB9jcKuH2xDQ-zTo-zTofRr0MQ257_W_ozx03X8_-wsCBLGp</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3073446733</pqid></control><display><type>article</type><title>β-Hydroxybutyrate Protects Against Cisplatin-Induced Renal Damage via Regulating Ferroptosis</title><source>PubMed (Medline)</source><source>Taylor & Francis</source><source>Publicly Available Content Database</source><creator>Tian, Ruixue ; Tang, Shuqin ; Zhao, Jingyu ; Hao, Yajie ; Zhao, Limei ; Han, Xiutao ; Wang, Xingru ; Zhang, Lijun ; Li, Rongshan ; Zhou, Xiaoshuang</creator><creatorcontrib>Tian, Ruixue ; Tang, Shuqin ; Zhao, Jingyu ; Hao, Yajie ; Zhao, Limei ; Han, Xiutao ; Wang, Xingru ; Zhang, Lijun ; Li, Rongshan ; Zhou, Xiaoshuang</creatorcontrib><description>Cisplatin is a particularly potent antineoplastic drug. However, its usefulness is restricted due to the induction of nephrotoxicity. More recent research has indicated that β-hydroxybutyrate (β-HB) protects against acute or chronic organ damage as an efficient healing agent. Nonetheless, the therapeutic mechanisms of β-HB in acute kidney damage caused by chemotherapeutic drugs remain unclear. Our study developed a model of cisplatin-induced acute kidney injury (AKI), which involved the administration of a ketogenic diet or β-HB. We analyzed blood urea nitrogen (BUN) and creatinine (Cr) levels in serum, and used western blotting and immunohistochemical staining to assess ferroptosis and the calcium/calmodulin-dependent kinase kinase 2 (Camkk2)/AMPK pathway. The mitochondrial morphology and function were examined. Additionally, we conducted
and
experiments using selective Camkk2 inhibitor or activator to investigate the protective mechanism of β-HB on cisplatin-induced AKI. Exogenous or endogenous β-HB effectively alleviated cisplatin-induced abnormally elevated levels of BUN and Cr and renal tubular necrosis
. Additionally, β-HB reduced ferroptosis biomarkers and increased the levels of anti-ferroptosis biomarkers in the kidney. β-HB also improved mitochondrial morphology and function. Moreover, β-HB significantly attenuated cisplatin-induced cell ferroptosis and damage
. Furthermore, western blotting and immunohistochemical staining indicated that β-HB may prevent kidney injury by regulating the Camkk2-AMPK pathway. The use of the Camkk2 inhibitor or activator verified the involvement of Camkk2 in the renal protection by β-HB. This study provided evidence of the protective effects of β-HB against cisplatin-induced nephrotoxicity and identified inhibited ferroptosis and Camkk2 as potential molecular mechanisms.</description><identifier>ISSN: 0886-022X</identifier><identifier>EISSN: 1525-6049</identifier><identifier>DOI: 10.1080/0886022X.2024.2354918</identifier><identifier>PMID: 38757723</identifier><language>eng</language><publisher>England: Taylor & Francis Ltd</publisher><subject>3-Hydroxybutyric Acid - pharmacology ; Acute Kidney Injury ; Acute Kidney Injury - chemically induced ; Acute Kidney Injury - metabolism ; Acute Kidney Injury - pathology ; Acute Kidney Injury - prevention & control ; AMP-activated protein kinase ; AMP-Activated Protein Kinases - metabolism ; AMPK ; Animals ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - toxicity ; Antineoplastic drugs ; Biomarkers ; Blood Urea Nitrogen ; Calcium-Calmodulin-Dependent Protein Kinase Kinase - metabolism ; Calmodulin ; Camkk2 ; Chemotherapy ; Cisplatin ; Cisplatin - adverse effects ; Cisplatin - toxicity ; Creatinine ; Creatinine - blood ; Cytology ; Disease Models, Animal ; Ferroptosis ; Ferroptosis - drug effects ; High fat diet ; Humans ; Ketogenesis ; Kidney - drug effects ; Kidney - metabolism ; Kidney - pathology ; Kidneys ; Low carbohydrate diet ; Male ; Mice ; Mice, Inbred C57BL ; Mitochondria - drug effects ; Mitochondria - metabolism ; Molecular modelling ; Morphology ; nephrotoxicity ; Signal Transduction - drug effects ; Western blotting ; β-hydroxybutyrate</subject><ispartof>Renal failure, 2024-12, Vol.46 (1), p.2354918-2354918</ispartof><rights>2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2024 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c506t-daad1d418d694003aad4c246c09006ea025af5038be1a2a03a9de49ac343b03d3</citedby><cites>FETCH-LOGICAL-c506t-daad1d418d694003aad4c246c09006ea025af5038be1a2a03a9de49ac343b03d3</cites><orcidid>0000-0003-1193-9913</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104694/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3073446733?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38757723$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tian, Ruixue</creatorcontrib><creatorcontrib>Tang, Shuqin</creatorcontrib><creatorcontrib>Zhao, Jingyu</creatorcontrib><creatorcontrib>Hao, Yajie</creatorcontrib><creatorcontrib>Zhao, Limei</creatorcontrib><creatorcontrib>Han, Xiutao</creatorcontrib><creatorcontrib>Wang, Xingru</creatorcontrib><creatorcontrib>Zhang, Lijun</creatorcontrib><creatorcontrib>Li, Rongshan</creatorcontrib><creatorcontrib>Zhou, Xiaoshuang</creatorcontrib><title>β-Hydroxybutyrate Protects Against Cisplatin-Induced Renal Damage via Regulating Ferroptosis</title><title>Renal failure</title><addtitle>Ren Fail</addtitle><description>Cisplatin is a particularly potent antineoplastic drug. However, its usefulness is restricted due to the induction of nephrotoxicity. More recent research has indicated that β-hydroxybutyrate (β-HB) protects against acute or chronic organ damage as an efficient healing agent. Nonetheless, the therapeutic mechanisms of β-HB in acute kidney damage caused by chemotherapeutic drugs remain unclear. Our study developed a model of cisplatin-induced acute kidney injury (AKI), which involved the administration of a ketogenic diet or β-HB. We analyzed blood urea nitrogen (BUN) and creatinine (Cr) levels in serum, and used western blotting and immunohistochemical staining to assess ferroptosis and the calcium/calmodulin-dependent kinase kinase 2 (Camkk2)/AMPK pathway. The mitochondrial morphology and function were examined. Additionally, we conducted
and
experiments using selective Camkk2 inhibitor or activator to investigate the protective mechanism of β-HB on cisplatin-induced AKI. Exogenous or endogenous β-HB effectively alleviated cisplatin-induced abnormally elevated levels of BUN and Cr and renal tubular necrosis
. Additionally, β-HB reduced ferroptosis biomarkers and increased the levels of anti-ferroptosis biomarkers in the kidney. β-HB also improved mitochondrial morphology and function. Moreover, β-HB significantly attenuated cisplatin-induced cell ferroptosis and damage
. Furthermore, western blotting and immunohistochemical staining indicated that β-HB may prevent kidney injury by regulating the Camkk2-AMPK pathway. The use of the Camkk2 inhibitor or activator verified the involvement of Camkk2 in the renal protection by β-HB. This study provided evidence of the protective effects of β-HB against cisplatin-induced nephrotoxicity and identified inhibited ferroptosis and Camkk2 as potential molecular mechanisms.</description><subject>3-Hydroxybutyric Acid - pharmacology</subject><subject>Acute Kidney Injury</subject><subject>Acute Kidney Injury - chemically induced</subject><subject>Acute Kidney Injury - metabolism</subject><subject>Acute Kidney Injury - pathology</subject><subject>Acute Kidney Injury - prevention & control</subject><subject>AMP-activated protein kinase</subject><subject>AMP-Activated Protein Kinases - metabolism</subject><subject>AMPK</subject><subject>Animals</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - toxicity</subject><subject>Antineoplastic drugs</subject><subject>Biomarkers</subject><subject>Blood Urea Nitrogen</subject><subject>Calcium-Calmodulin-Dependent Protein Kinase Kinase - metabolism</subject><subject>Calmodulin</subject><subject>Camkk2</subject><subject>Chemotherapy</subject><subject>Cisplatin</subject><subject>Cisplatin - adverse effects</subject><subject>Cisplatin - toxicity</subject><subject>Creatinine</subject><subject>Creatinine - blood</subject><subject>Cytology</subject><subject>Disease Models, Animal</subject><subject>Ferroptosis</subject><subject>Ferroptosis - drug effects</subject><subject>High fat diet</subject><subject>Humans</subject><subject>Ketogenesis</subject><subject>Kidney - drug effects</subject><subject>Kidney - metabolism</subject><subject>Kidney - pathology</subject><subject>Kidneys</subject><subject>Low carbohydrate diet</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mitochondria - drug effects</subject><subject>Mitochondria - metabolism</subject><subject>Molecular modelling</subject><subject>Morphology</subject><subject>nephrotoxicity</subject><subject>Signal Transduction - drug effects</subject><subject>Western blotting</subject><subject>β-hydroxybutyrate</subject><issn>0886-022X</issn><issn>1525-6049</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkt9u0zAUhyMEYt3gEUCRuOEm5fhvnCs0dYxVmgRCIHGDrBPbDanSuNjORF-LB9kz4a7dxLiyfPydTz72ryheEZgTUPAOlJJA6fc5BcrnlAneEPWkmBFBRSWBN0-L2Z6p9tBJcRrjGoAIVdPnxQlTtahrymbFj9s_1dXOBv97105pFzC58nPwyZkUy_MO-zGmctHH7YCpH6vlaCfjbPnFjTiUF7jBzpU3PeZCN90hXXnpQvDb5GMfXxTPVjhE9_K4nhXfLj98XVxV158-Lhfn15URIFNlES2xnCgrGw7A8pYbyqWBBkA6BCpwJYCp1hGkmIHGOt6gYZy1wCw7K5YHr_W41tvQbzDstMde3xV86DSG1JvBaZ57lGzUyvCaS55VpnXcNZa3pLY1Ztf7g2s7tRtnjRtTwOGR9PHJ2P_Unb_RhBDgeYBseHs0BP9rcjHpTR-NGwYcnZ-iZiCklKwhIqNv_kPXfgr5bfdUzTiXNWOZEgfKBB9jcKuH2xDQ-zTo-zTofRr0MQ257_W_ozx03X8_-wsCBLGp</recordid><startdate>202412</startdate><enddate>202412</enddate><creator>Tian, Ruixue</creator><creator>Tang, Shuqin</creator><creator>Zhao, Jingyu</creator><creator>Hao, Yajie</creator><creator>Zhao, Limei</creator><creator>Han, Xiutao</creator><creator>Wang, Xingru</creator><creator>Zhang, Lijun</creator><creator>Li, Rongshan</creator><creator>Zhou, Xiaoshuang</creator><general>Taylor & Francis Ltd</general><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7XB</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-1193-9913</orcidid></search><sort><creationdate>202412</creationdate><title>β-Hydroxybutyrate Protects Against Cisplatin-Induced Renal Damage via Regulating Ferroptosis</title><author>Tian, Ruixue ; Tang, Shuqin ; Zhao, Jingyu ; Hao, Yajie ; Zhao, Limei ; Han, Xiutao ; Wang, Xingru ; Zhang, Lijun ; Li, Rongshan ; Zhou, Xiaoshuang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c506t-daad1d418d694003aad4c246c09006ea025af5038be1a2a03a9de49ac343b03d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>3-Hydroxybutyric Acid - pharmacology</topic><topic>Acute Kidney Injury</topic><topic>Acute Kidney Injury - chemically induced</topic><topic>Acute Kidney Injury - metabolism</topic><topic>Acute Kidney Injury - pathology</topic><topic>Acute Kidney Injury - prevention & control</topic><topic>AMP-activated protein kinase</topic><topic>AMP-Activated Protein Kinases - metabolism</topic><topic>AMPK</topic><topic>Animals</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - toxicity</topic><topic>Antineoplastic drugs</topic><topic>Biomarkers</topic><topic>Blood Urea Nitrogen</topic><topic>Calcium-Calmodulin-Dependent Protein Kinase Kinase - metabolism</topic><topic>Calmodulin</topic><topic>Camkk2</topic><topic>Chemotherapy</topic><topic>Cisplatin</topic><topic>Cisplatin - adverse effects</topic><topic>Cisplatin - toxicity</topic><topic>Creatinine</topic><topic>Creatinine - blood</topic><topic>Cytology</topic><topic>Disease Models, Animal</topic><topic>Ferroptosis</topic><topic>Ferroptosis - drug effects</topic><topic>High fat diet</topic><topic>Humans</topic><topic>Ketogenesis</topic><topic>Kidney - drug effects</topic><topic>Kidney - metabolism</topic><topic>Kidney - pathology</topic><topic>Kidneys</topic><topic>Low carbohydrate diet</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mitochondria - drug effects</topic><topic>Mitochondria - metabolism</topic><topic>Molecular modelling</topic><topic>Morphology</topic><topic>nephrotoxicity</topic><topic>Signal Transduction - drug effects</topic><topic>Western blotting</topic><topic>β-hydroxybutyrate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tian, Ruixue</creatorcontrib><creatorcontrib>Tang, Shuqin</creatorcontrib><creatorcontrib>Zhao, Jingyu</creatorcontrib><creatorcontrib>Hao, Yajie</creatorcontrib><creatorcontrib>Zhao, Limei</creatorcontrib><creatorcontrib>Han, Xiutao</creatorcontrib><creatorcontrib>Wang, Xingru</creatorcontrib><creatorcontrib>Zhang, Lijun</creatorcontrib><creatorcontrib>Li, Rongshan</creatorcontrib><creatorcontrib>Zhou, Xiaoshuang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Renal failure</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tian, Ruixue</au><au>Tang, Shuqin</au><au>Zhao, Jingyu</au><au>Hao, Yajie</au><au>Zhao, Limei</au><au>Han, Xiutao</au><au>Wang, Xingru</au><au>Zhang, Lijun</au><au>Li, Rongshan</au><au>Zhou, Xiaoshuang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>β-Hydroxybutyrate Protects Against Cisplatin-Induced Renal Damage via Regulating Ferroptosis</atitle><jtitle>Renal failure</jtitle><addtitle>Ren Fail</addtitle><date>2024-12</date><risdate>2024</risdate><volume>46</volume><issue>1</issue><spage>2354918</spage><epage>2354918</epage><pages>2354918-2354918</pages><issn>0886-022X</issn><eissn>1525-6049</eissn><abstract>Cisplatin is a particularly potent antineoplastic drug. However, its usefulness is restricted due to the induction of nephrotoxicity. More recent research has indicated that β-hydroxybutyrate (β-HB) protects against acute or chronic organ damage as an efficient healing agent. Nonetheless, the therapeutic mechanisms of β-HB in acute kidney damage caused by chemotherapeutic drugs remain unclear. Our study developed a model of cisplatin-induced acute kidney injury (AKI), which involved the administration of a ketogenic diet or β-HB. We analyzed blood urea nitrogen (BUN) and creatinine (Cr) levels in serum, and used western blotting and immunohistochemical staining to assess ferroptosis and the calcium/calmodulin-dependent kinase kinase 2 (Camkk2)/AMPK pathway. The mitochondrial morphology and function were examined. Additionally, we conducted
and
experiments using selective Camkk2 inhibitor or activator to investigate the protective mechanism of β-HB on cisplatin-induced AKI. Exogenous or endogenous β-HB effectively alleviated cisplatin-induced abnormally elevated levels of BUN and Cr and renal tubular necrosis
. Additionally, β-HB reduced ferroptosis biomarkers and increased the levels of anti-ferroptosis biomarkers in the kidney. β-HB also improved mitochondrial morphology and function. Moreover, β-HB significantly attenuated cisplatin-induced cell ferroptosis and damage
. Furthermore, western blotting and immunohistochemical staining indicated that β-HB may prevent kidney injury by regulating the Camkk2-AMPK pathway. The use of the Camkk2 inhibitor or activator verified the involvement of Camkk2 in the renal protection by β-HB. This study provided evidence of the protective effects of β-HB against cisplatin-induced nephrotoxicity and identified inhibited ferroptosis and Camkk2 as potential molecular mechanisms.</abstract><cop>England</cop><pub>Taylor & Francis Ltd</pub><pmid>38757723</pmid><doi>10.1080/0886022X.2024.2354918</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-1193-9913</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0886-022X |
ispartof | Renal failure, 2024-12, Vol.46 (1), p.2354918-2354918 |
issn | 0886-022X 1525-6049 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_43438698fc474643a9cbe4e9d4b17d7a |
source | PubMed (Medline); Taylor & Francis; Publicly Available Content Database |
subjects | 3-Hydroxybutyric Acid - pharmacology Acute Kidney Injury Acute Kidney Injury - chemically induced Acute Kidney Injury - metabolism Acute Kidney Injury - pathology Acute Kidney Injury - prevention & control AMP-activated protein kinase AMP-Activated Protein Kinases - metabolism AMPK Animals Antineoplastic Agents - adverse effects Antineoplastic Agents - toxicity Antineoplastic drugs Biomarkers Blood Urea Nitrogen Calcium-Calmodulin-Dependent Protein Kinase Kinase - metabolism Calmodulin Camkk2 Chemotherapy Cisplatin Cisplatin - adverse effects Cisplatin - toxicity Creatinine Creatinine - blood Cytology Disease Models, Animal Ferroptosis Ferroptosis - drug effects High fat diet Humans Ketogenesis Kidney - drug effects Kidney - metabolism Kidney - pathology Kidneys Low carbohydrate diet Male Mice Mice, Inbred C57BL Mitochondria - drug effects Mitochondria - metabolism Molecular modelling Morphology nephrotoxicity Signal Transduction - drug effects Western blotting β-hydroxybutyrate |
title | β-Hydroxybutyrate Protects Against Cisplatin-Induced Renal Damage via Regulating Ferroptosis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T15%3A46%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=%CE%B2-Hydroxybutyrate%20Protects%20Against%20Cisplatin-Induced%20Renal%20Damage%20via%20Regulating%20Ferroptosis&rft.jtitle=Renal%20failure&rft.au=Tian,%20Ruixue&rft.date=2024-12&rft.volume=46&rft.issue=1&rft.spage=2354918&rft.epage=2354918&rft.pages=2354918-2354918&rft.issn=0886-022X&rft.eissn=1525-6049&rft_id=info:doi/10.1080/0886022X.2024.2354918&rft_dat=%3Cproquest_doaj_%3E3056663915%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c506t-daad1d418d694003aad4c246c09006ea025af5038be1a2a03a9de49ac343b03d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3073446733&rft_id=info:pmid/38757723&rfr_iscdi=true |